Clinical Trial Update: Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Ravulizumab for thrombotic microangiopathy after hematopoietic stem cell transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombotic Microangiopathy

Drugs mentioned

• ULTOMIRIS (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Thrombotic Microangiopathy | Phase 3 | Status: COMPLETED